KCNN4 and early-onset autosomal dominant Alzheimer disease: Based on its safety and efficacy as a KCa3.1 blocker, senicapoc has also been proposed for the treatment of neuropathic pain [43], and is currently being trialed in a phase II study for mild and prodromal Alzheimer’s disease with the goal of demonstrating biological activity and target engagement in humans with early AD (NCT04804241).